PharmaCann Shuts Denver Grow Facility, Cuts 132 Jobs as Colorado Cannabis Contracts
Advertisement
Chicago-based PharmaCann Inc., the largest privately held cannabis company in the United States, is permanently shutting down its massive Denver cultivation facility and eliminating 132 jobs. The closure, announced March 21, underscores the deepening financial squeeze gripping Colorado's once-booming cannabis industry — and signals a broader reckoning for operators who expanded aggressively during the market's peak years.
The facility at 5141 N. National Western Drive, one of the largest grow operations in Colorado, will cease all operations on May 20. Every position at the site will be eliminated, and the company has indicated the closure is permanent.
Key Takeaways
- Wholesale flower prices in Colorado have collapsed 62 percent since 2021, making in-house cultivation economically unviable for many operators.
- Colorado has lost nearly half its licensed recreational growers since 2021, with the count dropping from 976 to 488.
- PharmaCann is permanently closing its Denver cultivation facility on May 20, eliminating 132 jobs at one of Colorado's largest grow operations.
Table of Contents
- A Peak-Market Acquisition Gone Wrong
- Colorado's Grow Industry in Free Fall
- The Rise of the Asset-Light Model
- Broader Industry Implications
- What This Means for Denver and Colorado Workers
A Peak-Market Acquisition Gone Wrong
PharmaCann acquired the Denver grow as part of its purchase of LivWell Enlightened Health in February 2022, a deal struck near the apex of the cannabis market boom. At that time, wholesale flower prices were elevated, consumer demand was surging, and operators were racing to lock in cultivation capacity.
The timing could not have been worse. Since that acquisition, wholesale cannabis flower prices in Colorado have cratered. According to industry data, the average price per pound plummeted from $1,721 in 2021 to just $648 by December 2025 — a decline of more than 62 percent in four years.
At those price levels, purchasing wholesale flower on the open market has become significantly cheaper than growing it in-house, a dynamic that has upended the economics of large-scale cultivation.
The collapse in flower prices reflects chronic oversupply in Colorado's mature market. As one of the first states to legalize adult-use cannabis in 2014, Colorado attracted enormous investment in cultivation capacity. But consumer demand has plateaued while licensed grow operations flooded the market with product, triggering a sustained price war that has squeezed margins to unsustainable levels.
Colorado's Grow Industry in Free Fall
PharmaCann's closure is not an isolated event. Colorado's licensed recreational grower count has been cut roughly in half, falling from approximately 976 operations in December 2021 to 488 by December 2025. That is nearly 500 cultivation licenses surrendered, lapsed, or revoked in just four years.
The attrition reflects a brutal Darwinian process playing out across Colorado's cannabis sector. Operators with high fixed costs — particularly those locked into expensive real estate leases and carrying debt from expansion-era investments — have been the most vulnerable. Many have been forced to choose between operating at a loss or shutting down entirely.
PharmaCann itself has been shedding Colorado assets for months. The company recently sold its 17 LivWell-branded dispensaries to Minneapolis-based Vireo Growth for $49 million in stock, though the Denver grow facility was not included in that transaction. Separately, PharmaCann is also closing a cultivation facility in Dwight, Illinois, where 82 additional jobs are being cut.
The company has reportedly defaulted on 11 leases across its portfolio.
The Rise of the Asset-Light Model
PharmaCann's retreat from cultivation reflects a strategic shift that is reshaping the cannabis industry. Rather than growing their own flower, an increasing number of operators are adopting what analysts call an "asset-light" model — purchasing wholesale product from third-party cultivators instead of maintaining expensive in-house grow operations.
Vireo Growth, the company that acquired PharmaCann's dispensaries, has been an outspoken advocate of this approach. By avoiding the capital expenditure and operating costs associated with large-scale cultivation, asset-light operators can maintain higher margins and greater flexibility to adjust their product mix based on market conditions.
The model has gained traction as wholesale prices have dropped to the point where buying flower is consistently cheaper than growing it. For vertically integrated [Quick Definition: A company that controls every stage from cultivation to retail] operators like PharmaCann, that math has become impossible to ignore. The Denver facility's overhead — including labor, energy, nutrients, compliance costs, and lease payments — simply cannot compete with the bargain-basement pricing available on Colorado's wholesale market.
Broader Industry Implications
Colorado's cannabis contraction is a cautionary tale for the national industry. Markets that have followed similar trajectories — including Oregon, Washington, and increasingly California — have seen comparable patterns of oversupply, price compression, and operator attrition.
The U.S. cannabis industry as a whole faces a profitability crisis. According to recent industry data, only 27 percent of cannabis companies were profitable in 2024, down from 42 percent in 2022. While total industry revenue continues to grow — projected to reach $47 billion nationally in 2026 — that growth has not translated into sustainable profits for most operators.
The financial pressure is compounded by IRS Section 280E [Quick Definition: IRS code barring cannabis businesses from deducting normal expenses like rent and payroll], which prevents cannabis businesses from deducting standard operating expenses. For a cultivation facility like PharmaCann's Denver operation, that means the company has been paying taxes on gross revenue rather than net income, dramatically amplifying losses during a period of depressed wholesale prices.
Potential rescheduling to Schedule III [Quick Definition: A mid-level federal drug classification including ketamine and testosterone] could provide relief by eliminating the 280E tax burden, but that process remains months or potentially years away. For companies already hemorrhaging cash, the cavalry may arrive too late.
What This Means for Denver and Colorado Workers
The loss of 132 jobs at the National Western Drive facility adds to a growing toll of cannabis industry layoffs in Colorado. For workers in cannabis cultivation — many of whom developed specialized skills in growing, processing, and compliance — the contracting market presents difficult choices. Some will find positions at surviving operations, but the shrinking number of licensed growers means competition for remaining positions is intensifying.
Denver's cannabis sector, once hailed as a model for how legalization could create jobs and economic opportunity, is being forced to reckon with the same market forces that shape any commodity industry. When supply outstrips demand and barriers to entry are low, prices fall, margins compress, and consolidation follows.
The question now is whether Colorado's surviving operators can find sustainable footing at lower price points, or whether the contraction still has further to run. With wholesale prices showing few signs of recovery and the licensed grower count still declining, the answer may not arrive for some time.
Pull-Quote Suggestions:
"The company recently sold its 17 LivWell-branded dispensaries to Minneapolis-based Vireo Growth for $49 million in stock, though the Denver grow facility was not included in that transaction."
"While total industry revenue continues to grow — projected to reach $47 billion nationally in 2026 — that growth has not translated into sustainable profits for most operators."
"According to industry data, the average price per pound plummeted from $1,721 in 2021 to just $648 by December 2025 — a decline of more than 62 percent in four years."
Why It Matters: PharmaCann is closing its massive Denver cannabis grow and cutting 132 jobs. Here's why Colorado's cannabis industry is shrinking fast in 2026.